Status:
COMPLETED
Corticosteroid Pulse After Ablation
Lead Sponsor:
Minneapolis Heart Institute Foundation
Collaborating Sponsors:
Abbott Medical Devices
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Radiofrequency ablation is an effective treatment for atrial fibrillation. However, about 20% of the time the atrial fibrillation recurs. Steroids given after the ablation may decrease inflammation ca...
Detailed Description
Atrial fibrillation, a common arrhythmia, is the source of considerable morbidity. Prevalence of atrial fibrillation in adults is 0.5%, increasing to 10% in those patients over the age of seventy five...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Drug refractory, symptomatic paroxysmal atrial fibrillation
Exclusion
- Contraindication to solumedrol
- Persistent or permanent Atrial Fibrillation
- Previous history of radiofrequency ablation for atrial fibrillation
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00807586
Start Date
December 1 2008
End Date
December 1 2013
Last Update
August 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abbott Northwestern Hospital
Minneapolis, Minnesota, United States, 55407